Table 3. Evolution of qualitative indicators after ophthalmologic examination of the study patients according with their treatment.
| Parameters | Total | Bromfenac 0.09% | Nepafenac 0.1% | Diclofenac sodium 0.1% | P |
| Biomicroscopy | |||||
| Decreased | 44 (20.1) | 19 (26.8) | 11 (17.2) | 14 (16.7) | 0.199 |
| Unchanged | 173 (79.0) | 52 (73.2) | 53 (82.8) | 68 (81.0) | |
| Increased | 2 (0.9) | 0 (0.0) | 0 (0.0) | 2 (2.4) | |
| Tyndall effect | |||||
| Decreased | 147 (67.1) | 39 (54.9) | 53 (82.8) | 55 (65.5) | <0.001 |
| Unchanged | 70 (32.0) | 31 (43.7) | 10 (15.6) | 29 (34.5) | |
| Increased | 2 (0.9) | 1 (1.4) | 1 (1.6) | 0 (0.0) | |
| Degree of pain | |||||
| Decreased | 26 (10.9) | 4 (5.1) | 6 (7.9) | 16 (19.0) | 0.026 |
| Unchanged | 211 (88.7) | 73 (93.6) | 70 (92.1) | 68 (81.0) | |
| Increased | 1 (0.4) | 1 (1.3) | 0 (0.0) | 0 (0.0) | |
| Blurred vision | |||||
| Decreased | 11 (4.6) | 0 (0.0) | 0 (0.0) | 11 (13.1) | <0.001 |
| Unchanged | 225 (94.5) | 77 (98.7) | 75 (98.7) | 73 (86.9) | |
| Increased | 2 (0.8) | 1 (1.3) | 1 (1.3) | 0 (0.0) | |
| Foreing body sensation | |||||
| Decreased | 27 (11.3) | 8 (10.3) | 2 (2.6) | 17 (20.2) | 0.009 |
| Unchanged | 209 (87.8) | 69 (88.5) | 74 (97.4) | 66 (78.6) | |
| Increased | 2 (0.8) | 1 (1.3) | 0 (0.0) | 1 (1.2) | |
| Photophobia | |||||
| Decreased | 5 (2.1) | 0 (0.0) | 1 (1.3) | 4 (4.8) | 0.146 |
| Unchanged | 232 (97.5) | 77 (98.7) | 75 (98.7) | 80 (95.2) | |
| Increased | 1 (0.4) | 1 (1.3) | 0 (0.0) | 0 (0.0) |
n (%)